Alligator Bioscience AB: Business Overview, Financials & Competitive Analysis
Alligator Bioscience AB scores 3/10 on the AskCyborg Cyborg Score (Weak). High-risk clinical-stage oncology play with promising Phase 2 data but questionable path to profitability and significant capital requirements for Phase 3. Early-stage clinical biotech with significant clinical promise in mitazalimab but facing severe financial distress. Stock has collapsed 98%+ in the past year, recent capital raises indicate liquidity concerns.
What is Alligator Bioscience AB's industry? Alligator Bioscience AB (alligatorbioscience.se) operates in Biotechnology - Oncology/Immuno-oncology. AskCyborg classifies Alligator Bioscience AB under Biotechnology - Oncology/Immuno-oncology in its company registry.
Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. The company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and ha...
Cyborg Score thesis
High-risk clinical-stage oncology play with promising Phase 2 data but questionable path to profitability and significant capital...
Read the full analyst-debate transcript →Get the Latest Alligator Bioscience AB Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAlligator Bioscience AB Overview
Pro stress-test →Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. The company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 30-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.
Strategic Profile
Pro stress-test →Alligator is a clinical-stage biotechnology company focused on the CD40 receptor with a validated approach that promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment. The company develops products using technology platforms including ALLIGATOR-GOLD, ALLIGATOR-FAB, FIND, and RUBY, with collaboration agreements with Aptevo Therapeutics, Orion Corporation, BioArctic AB, and Abclon Inc.
Competitive Landscape
Pro stress-test →Alligator specializes in tumor-targeted immunotherapies, particularly agonist mono- and bispecific antibodies, active in early stages of drug development from concept to Phase II clinical trials. Primary competitors in CD40 and immuno-oncology space include larger established biotechs and pharma companies with more diversified portfolios and stronger balance sheets.
Industry Context
Alligator Bioscience AB operates in Biotechnology - Oncology/Immuno-oncology.
Key facts
Founded: 2000 · Headquarters: Lund, Sweden · Employees: ~45 · Revenue: SEK 57.7M (2024) · Market cap: SEK 45-102M (~$4.5-10M USD)